FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor...

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically...

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive...

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024...

Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically...

CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of...

CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year...

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe...

Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of...